ArticleBMC microbiology2025
Bioremediation and optimization of selenate reduction by a novel Bacillus cabrialesii strain (Se1) producing red selenium nanoparticles with potential antibacterial activity.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to isolate and identify selenate-reducing bacteria from polluted Egyptian soil. The isolated bacteria could be used to bioremediate contaminated soils and wastewater. MATERIALS AND
methodsA potent selenate-reducing bacterium was isolated for optimum production of selenium nanoparticles using a Box-Behnken design (BBD) of the response surface methodology.
resultsA novel selenate-reducing bacterium, designated Se1, was isolated from an industrial effluent soil in Cairo, Egypt. When cultured in enrichment basal medium and then on nutrient agar medium supplemented with 0.945 g L
conclusionThis study presents the first documented evidence of selenate reduction by Bacillus cabrialesii, highlighting its potential applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.